About Adamas

Adamas is a pharmaceutical company that develops new medicines to improve the daily lives of those affected by chronic neurologic disorders. Approximately 36 million people in the United States suffer from conditions such as Alzheimer’s disease, Parkinson’s disease (PD), multiple sclerosis and epilepsy. Symptoms associated with these disorders can be treated sub-optimally due to tolerability issues, which may limit the amount of drug that is present when patients need relief.

Adamas has pioneered a platform to develop medicines for chronic neurologic disorders based upon an understanding of time-dependent biologic processes responsible for disease activity and drug response. We translate this understanding into medicines to provide demonstrable symptomatic relief from chronic neurologic disorders without additional tolerability issues. With this platform we:

  • discover insights about temporal patterns of disease activity and drug response
  • identify known drugs with potential activity in targeted disorders
  • invent a synchronized drug profile to match underlying disease activity and drug response patterns
  • develop new medicines that release the drug to match the desired drug profile, first as single agents and then in fixed-dose combinations
  • commercialize new products alone and with partners

We call these medicines chrono-synchronous therapies.

We have developed a portfolio of CSTs to address chronic neurologic disorders. Our lead program, ADS-5102, developed initially for levodopa-induced dyskinesia (LID) in patients with Parkinson’s disease, is currently being evaluated by the U.S. Food and Drug Administration (FDA) for potential approval in 2017.  ADS-5102 has additional opportunities to provide potentially symptomatic treatment of other chronic neurologic disorders such as multiple sclerosis walking impairment, post stroke walking impairment, and several other indications. ADS-4101 is our most recent clinical development asset, entering the clinic for the improved control of epileptic seizures. Additionally, through our license to Allergan, our portfolio includes two medicines commercially available in the United States for indications relating to Alzheimer’s disease: Namzaric® (memantine hydrochloride extended-release and donepezil hydrochloride) capsules and Namenda XR® (memantine hydrochloride) extended-release capsules. Adamas is eligible to receive royalties on sales of Namenda XR® and Namzaric® beginning in June of 2018 and May of 2020, respectively. Our business strategy is to continue to discover, develop and commercialize new treatment solutions for patients independently or in collaboration with partners.

NAMENDA XR® and NAMZARIC® are registered trademarks of Merz Pharma GmbH & Co. KGaA.

Developing chrono-synchronous therapies to improve the daily lives of people affected by chronic neurologic disorders.

About Adamas
  • Headquarters:
    Emeryville, Calif.
  • Employees: ~70
  • Initial Public Offering: April 2014
  • Nasdaq: ADMS